PATH | VRL
Menu

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine Against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

This article, published in PLoS ONE, shares the results of a Phase 1 trial exploring the safety, immunogenicity, and transmission-blocking activity of a malaria transmission-blocking vaccine candidate, Pfs25-EPA conjugates formulated with Alhydrogel®. The study sequentially exposed three groups of participants with varying doses and schedules of the vaccine. Results of the study found that the vaccine was well tolerated and generated immune responses in all participants after three doses, however, the vaccine did not produce levels of immunogenic reaction that would interrupt malaria transmission. The article recommends further study of alternate conjugates and adjuvants for Pfs25-EPA/Alhydrogel® and further testing in malaria-exposed populations.

Author: Talaat KR, Ellis RD, Hurd J, et al.

Published: 2016

» Visit web page (English)

(Located at journals.plos.org)

Citation: Talaat KR, Ellis RD, Hurd J, et al. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine Against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PLoS ONE. 2016;11(10):e0163144.

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global